Type 1 diabetes
Conditions
Interventions
Change bolus inclement
Sponsors
Tokyo Metropolitan Children Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who visited the Department of Endocrinology and Metabolism at Tokyo Metropolitan Children Medical Center between January 2023 and March 2028 will be eligible for inclusion. Differences in the type of rapid-acting insulin used in the insulin pump and variations in insulin pump settings will not be considered as exclusion criteria. Inclusion Criteria: Patients diagnosed with type 1 diabetes mellitus; Patients younger than 20 years of age; Patients using the AHCL (Advanced Hybrid Closed Loop) function; Patients with both sensor usage and SmartGuard usage 70% or more; Patients or their legally authorized representatives who have received sufficient explanation of the study and provided written informed consent based on their free will and full understanding.
Exclusion criteria
Exclusion criteria: Patients whose carbohydrate ratio, active insulin time, or SmartGuard target glucose settings were changed during the study period. Patients whose insulin preparation was changed during the study period. Patients who developed thyroid dysfunction during the study period. Patients who are considered inappropriate for participation in the study by the principal investigator for any other reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in TIR from one month before to two months after bolus increment reduction during AHCL therapy. | — |
Countries
Japan
Contacts
Public ContactTomohiro Nagata
Tokyo Metropolitan Children Medical Center Department of Endocrinology and Metabolism
Outcome results
None listed